LLY

Business Context and Reporting Period

This Form 10-Q covers Eli Lilly and Company for the quarter and nine months ended September 30, 2006. The company operates primarily in the pharmaceutical products segment, with animal health operations included in this segment due to immateriality. The reporting period reflects strong sales growth driven by key products including Cymbalta, Byetta, Forteo, and Alimta, alongside ongoing legal challenges related to Zyprexa.

Key Financial Metrics

Note: Total Debt is the sum of Short-term borrowings ($334.2M) and Long-term debt ($4,553.3M) as of Sept 30, 2006. Q3 Operating Cash Flow is not explicitly provided in the text, only the 9-month figure.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% in Q3 and 6% for the nine months ended Sept 30, 2006, compared to the prior year. U.S. sales grew 9% in both periods, while international sales grew 5% (Q3) and 3% (9M).
• Profitability: Net income rose 10% in Q3 and nearly doubled (98%) for the nine-month period. The 9M 2005 comparison is significantly impacted by a $1.07 billion pre-tax product liability charge recorded in Q2 2005.
• Product Performance: Cymbalta sales surged 91% in Q3 and 98% for the nine months. Forteo sales increased 45% (Q3) and 56% (9M). Conversely, Fluoxetine products declined 30% and Anti-infectives dropped 44% in Q3.
• Balance Sheet: Cash and cash equivalents decreased from $3.01 billion (Dec 31, 2005) to $2.17 billion (Sept 30, 2006). Total debt decreased by $1.61 billion year-to-date due to repayments.

Guidance, Outlook, and Risks

Guidance and Outlook

• 2006 EPS: Management expects full-year 2006 earnings per share in the range of $3.07 to $3.18.
• Sales Growth: Full-year 2006 sales growth is expected to be at the low end of the 7% to 9% range.
• Acquisition: On October 17, 2006, Lilly signed an agreement to acquire ICOS Corporation for approximately $2.1 billion in cash. This will bring full ownership of Cialis. The transaction is expected to close in late 2006 or early 2007 and will likely result in a one-time charge for acquired in-process research and development (IPR&D).
• Restructuring: A plan to close the Hamburg, Germany facility was approved, expected to result in a Q4 2006 charge of $40 million to $50 million (pretax).

Risks and Contingencies

• Zyprexa Litigation: Significant product liability lawsuits remain regarding diabetes risks. Approximately 1,500 lawsuits covering 9,700 claimants are pending, with trials scheduled for April 2007. Patent litigation regarding generic entry is on appeal.
• Government Investigations: Civil investigations are ongoing regarding marketing practices for Zyprexa, Prozac, and other products, including Medicaid best price reporting.
• Patent Disputes: Ongoing litigation regarding patents for Evista and Gemzar, with generic manufacturers challenging validity.
• Insurance Disputes: Carriers are contesting liability for Zyprexa product liability claims, creating uncertainty regarding recoveries.

Investor Verification Checklist

• Verify the status and potential financial impact of the pending Zyprexa product liability trials scheduled for April 2007.
• Confirm the closing timeline and specific IPR&D charge amount associated with the ICOS Corporation acquisition.
• Monitor the outcome of the Zyprexa patent appeal at the Court of Appeals for the Federal Circuit.
• Assess the progress of government investigations into marketing practices and potential fines or penalties.
• Review the final decision on the closure or sale of the Basingstoke and Mont St. Guibert European facilities.